Envudeucitinib (ESK-001) is Alumis's oral allosteric TYK2 inhibitor in Phase 3 development for moderate to severe plaque psoriasis.
Competing Products
Alumis
Alumis pioneers precision medicines to improve lives by targeting immune-mediated diseases with optimized, transformative therapies.
Founded with a mission to revolutionize the treatment of immune-mediated diseases, Alumis focuses on developing precision medicines that replace broad immunosuppression with targeted therapies. The company aims to alleviate the debilitating impact of these diseases without the life-limiting side effects associated with current treatments. Alumis leverages powerful data analytics to select the right target, molecule, indication, patient, and endpoint, resulting in optimized outcomes. Their innovative pipeline includes oral therapies designed to transform the lives of patients suffering from immune dysfunction.
Alumis has garnered attention for its pioneering approach and commitment to improving patient outcomes. While specific notable affiliated people and investors are not detailed, the company's achievements include advancing a robust pipeline of precision therapies and establishing a strong foundation in the biotech industry. Alumis's impact lies in its potential to set new standards in the treatment of immune-mediated diseases, offering hope and improved quality of life for patients who have exhausted other therapeutic options.
Alumis - M & A Snapshot
Alumis - Quick Facts
Who are Alumis' competitors?
Companies similar to Alumis include InnoCare Pharma, Takeda, Bristol Myers Squibb and Allorion Therapeutics.
When was Alumis founded?
Alumis was founded in 2021.
Where is Alumis' headquarters located?
Alumis' headquarters is located in South San Francisco, CA, US.